Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
High mobility group box 1 pseudogene 46 (HMGB1P46) is a processed pseudogene related to the HMGB family of non-histone DNA-binding proteins, most closely related to HMGB1 and/or HMGB2. Pseudogenes are genomic DNA sequences similar to normal genes but are nonfunctional; they usually lack the ability to encode a functional protein due to interruptions such as frameshift mutations or premature stop codons. While some pseudogenes are transcribed and can exert regulatory roles (e.g., as competitive endogenous RNAs influencing the behavior of their parent genes), there is currently no evidence in the literature supporting such coding, regulatory, or disease-related roles for HMGB1P46 specifically. Thus, it is not considered a drug target or clinical biomarker. The parental gene, HMGB1, is a well-characterized DNA-binding protein involved in chromatin dynamics, immune response, and inflammation, but the pseudogene does not share these functional roles.
Not a direct drug target; any possible mechanism would involve nucleic acid interactions or regulation of parental gene expression, not direct protein action
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on High mobility group box 1 pseudogene 46 (HMGB1P46).